Dr. William Vogel

Pathologist · UCLH · United Kingdom (GB) · Oncology

Tier 3STK-0016GoodOwner MSL JWJames Whitfield

Data minimisation

Consent status: Recorded. The name shown may be a pseudonym. Contact details, personal identifiers and remuneration fields are hidden for your role; only scientific-profile fields needed for engagement planning are displayed.

Specialty: Thoracic oncology
Disease interests: SCLC
Scientific interests: PD-L1 biomarkers
Engagement preference: Virtual
Advisory boards: 1
Publications: 11
Source system: Veeva CRM
Data quality: Good

Engagement plan

Cadence target for Tier 3: 1 per year (assumption)

Last engaged: 17 Jan 2026 (241 days ago)
Next planned contact: 17 Jan 2027
Last 6 months vs target: 0%
0 of 1 expected engagements

Insights from this stakeholder (0)

No insights captured from engagements with this stakeholder.

Engagement history (1)

All engagements including drafts, newest first

Date	Type	Format	MSL	Product	Topics	Insights	Flags	Status
17 Jan 2026	Scientific exchange	In person	James Whitfield	Vantrexa	PD-L1 testing turnaroundSequencing after progression+1	0	—	Reviewed	ENG-0055

Timeline

17 Jan 2026
Scientific exchange
PD-L1 testing turnaround, Sequencing after progression, Elderly / ECOG 2 patients

Related stakeholders (7)

UCLH

Dr. Chloé Dubois
Oncology pharmacist
Tier 3
Dr. Benedikt Lopez
Pathologist
Tier 3
Dr. Zoë Castellano
Renal pathologist
Tier 2
Dr. Daniel Kimura
Academic nephrologist
Tier 2
Dr. Tomoko Jensen
Renal pathologist
Tier 2
Dr. Gabriel Kimura
Dermatologist
Tier 1
Dr. Javier Tanaka
Dermatologist
Tier 3